Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Human papilloma virus vaccination and its real-life efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. "It's probably nothing, but…" Couples' experiences of pregnancy following an uncertain prenatal genetic result

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Current use of noninvasive prenatal testing in Europe, Australia and the USA: A graphical presentation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Implementation of exome sequencing in fetal diagnostics - data and experiences from a tertiary center in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Non-invasive prenatal testing and maternal obesity - A review

    Research output: Contribution to journalReviewResearchpeer-review

  1. Postnatal germ cell development in cryptorchid boys

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Review of injection techniques for spermatogonial stem cell transplantation

    Research output: Contribution to journalReviewResearchpeer-review

  3. Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
To enhance oocyte yield and pregnancy outcome in poor responder women undergoing IVF treatment, daily low dose GnRH antagonist administration was given during the late luteal phase to induce luteolysis and possibly secure a more synchronous cohort of recruitable follicles. An open extended pilot study in four Scandinavian fertility centers was done including 60 patients. Poor response was defined as when <or = 5 follicles developed in a preceding cycle following a long agonist protocol with the use of > 2000 IU FSH. GnRH antagonist (ganirelix) was given, 0.25 mg s.c. daily, from days 3 to 5 before expected start of menstruation and continued for 4-7 days. On cycle day 2-3 a starting dose of rFSH (300-400 IU/day) was given. At a leading follicle diameter of 14 mm, ganirelix administration was resumed until final oocyte maturation was induced with 10,000 IU hCG. GnRH antagonist only marginally affected the intercycle FSH rise; basal levels of FSH remained similar to those seen after 4 days of antagonist administration. The protocol effectively induced low LH levels and luteolysis, but daily administration of 350 IU rFSH (median) for 11 days only led to the collection of 3 oocytes in 49 oocyte retrievals resulting in 5 pregnancies (4 delivered). Despite GnRH antagonist administration in the late luteal phase and menstrual bleeding, FSH was not sufficiently reduced to secure a more synchronic cohort of recruitable follicles. Novel GnRH antagonists more specifically targeting FSH release may improve the stimulation results in poor responders.
Original languageEnglish
JournalActa Obstetricia et Gynecologica Scandinavica
Volume89
Issue number6
Pages (from-to)828-31
Number of pages4
ISSN0001-6349
DOIs
Publication statusPublished - 2010

ID: 32169914